Evidence map›Paper›PMID 28928769›Full record

ArticleGastroenterology research and practice2017

Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn's Disease.

Youyou Luo, Jindan Yu, Jingan Lou, Youhong Fang, Jie Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Contemporary clinical trials communications · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Youyou LuoDepartment of Gastroenterology, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, China.ORCID 0000-0002-0185-1371
Jindan YuDepartment of Gastroenterology, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, China.
Jingan LouDepartment of Gastroenterology, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, China.
Youhong FangDepartment of Gastroenterology, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, China.
Jie ChenDepartment of Gastroenterology, The Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, China.ORCID 0000-0002-3603-3213
Children's Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn's disease (CD).

methodsIn a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn's disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects. Data were measured at baseline and after 8 weeks of therapy.

resultsWe enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN. Clinical response (PCDAI) reduction ≥ 15 or final PCDAI ≤ 10 was achieved by 83.3% in the EEN group and 90.9% in the IFX group. Body mass index for age (BMIFA)

conclusionEEN provided similar improvements as IFX in clinical symptoms, mucosal healing, and BMI. EEN therapy has less adverse effects when compared with IFX. This trial is registered with the Clinical Registration Number: ChiCTR-OON-17010834.

Identifiers

PMID28928769
PMCPMC5591912
OpenAlexW2743895707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.